Company Description
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis.
In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure.
Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease.
The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 579 |
| CEO | Han Ying |
Contact Details
Address: 12770 High Bluff Drive, Suite 150 San Diego, California 92130 United States | |
| Phone | (619) 949-3681 |
| Website | gyretx.com |
Stock Details
| Ticker Symbol | GYRE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001124105 |
| CUSIP Number | 403783103 |
| ISIN Number | US4037831033 |
| Employer ID | 56-2020050 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Han Ying Ph.D. | Chief Executive Officer and Director |
| Songjiang Ma | President and Director |
| Ruoyu Chen | Chief Financial Officer |
| Weiguo Ye | Chief Operating Officer |
| Ping Zhang | Executive Chair |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 23, 2025 | 8-K | Current Report |
| May 23, 2025 | 424B5 | Filing |
| May 22, 2025 | 424B5 | Filing |
| May 22, 2025 | 8-K | Current Report |
| May 9, 2025 | 10-Q | Quarterly Report |
| May 9, 2025 | 8-K | Current Report |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 22, 2025 | ARS | Filing |
| Apr 21, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 21, 2025 | DEF 14A | Other definitive proxy statements |